1. Colditz GA, Tuden RL, Oster G: Rates of venous thrombosis after general surgery: Combined results of randomized clinical trials. Lancet2:143-143, 1986.
2.
2. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med151:933-938, 1991.
3.
3. Market A, Manzo RA, Bergelin RO, et al: Vascular reflux after deep vein thrombosis: Incidence and time of occurrence. J Vasc Surg15:377-382, 1992.
4.
4. Barritt DW, Jordan SC: Anticoagulant drugs and the treatment of pulmonary embolism: A control trial. Lancet1:1309-1312, 1960.
5.
5. Howard PA: Dalteparin: A low-molecular-weight heparin. Ann Pharmacother31:192-203, 1997.
6.
6. Alhenc-Gelas M, Jestin-Le GC, Vitoux JF, et al: Adjusted versus fixed doses of the low-molecularweight heparin fragmin in the treatment of deep vein thrombosis. Fragmin Study Group. Thromb Haemost71:698-702, 1994.
7.
7. Van Ryn-McKenna J, Cai L, Ofosu FA, et al: Neutralization of enoxaparin-induced bleeding by protamine sulfate. Thromb Haemost63:271-274, 1990.
8.
8. Kitka MJ, Keller MP, Humphrey PW, et al: Can lowmolecular-weight heparins and heparinoids be safely given with heparin-induced thrombocytopenia syndrome?Surgery114:705-710, 1993.
9.
9. Prandoni P, Lensing AW, Buller HR, et al: Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet339:441-445, 1992.
10.
10. Hull RD, Raskob GE, Pineo GF, et al: Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med326:975-982, 1992.
11.
11. Levine M, Gent M, Hirsh J, et al: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med334:677-681, 1996.
12.
12. Koopman MM, Prandoni P, Piovella F, et al: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med334:682-687, 1996.
13.
13. The Columbus Investigators. Low molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med337:657-662, 1997.
14.
14. Simonneau G, Sors H, Charbonnier B, et al: A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. N Engl J Med337:663-669, 1997.
15.
15. Hawkins DW, Langley PC, Krueger KP: Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. Am J Health-Syst Pharm54:1185-1190, 1997.
16.
16. Dedden P, Chang B, Nagel D: Pharmacy-managed program for home treatment of deep vein thrombosis with enoxaparin. Am J Heath-Syst Pharm54:1968-1972, 1997.
17.
17. Fejgin MD, Lourwood DL: Low-molecular-weight heparins and their use in obstetrics and gynecology. Obstet Gynecol Surv49:424-431, 1994.
18.
18. Gillis S, Sushan A, Elder A: Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy. Int J Gynaecol Obstet39:297-301, 1992.
